Drug Recall: Buspirone Tablets Over Manufacturing Process Deviations
Northwind Pharmaceuticals is recalling Buspirone Hydrochloride 7.5 mg tablets due to manufacturing process deviations. The FDA Class II recall affects bottles distributed nationwide.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. CGMP deviations without specific adverse events constitute a voluntary precautionary recall, which the rubric classifies as Moderate severity.
Plain-English summary
Northwind Pharmaceuticals LLC is recalling Buspirone Hydrochloride Tablets USP, 7.5 mg, supplied in 30-count bottles, NDC 51655-511-52. The FDA classified this as a Class II recall due to Current Good Manufacturing Practice (CGMP) deviations.
The affected product was distributed nationwide across the United States. The recall involves six bottles with lot number F117312201 and expiration date of June 30, 2024.
The recall was initiated voluntarily by Northwind Pharmaceuticals on March 16, 2023. The company notified customers through multiple channels including email, fax, letter, press release, telephone, and direct visits.
The recalled product
- Product
- BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE)
- Brand
- BUSPIRONE HYDROCHLORIDE
- Manufacturer
- Northwind Pharmaceuticals LLC
- Category
- Drug
- Hazard
- Affected units
- 6
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: F117312201
- Exp. Date 06/30/2024
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 7 recalled by Northwind Pharmaceuticals LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same brand · BUSPIRONE HYDROCHLORIDE
- LowBuspirone Hydrochloride Tablets 5 mg Recalled for Subpotency
FDA (Drugs) · 2026-05-13
- ModerateLisinopril Tablets Recalled for Stray Amlodipine Tablet Contamination
FDA (Drugs) · 2023-11-29
- HighBuspirone Hydrochloride Tablets Recalled Due To Amlodipine Contamination Risk
FDA (Drugs) · 2023-11-29
- ModerateAccord Healthcare Recalls Buspirone Hydrochloride Due to Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- HighFDA recalls Buspirone Hydrochloride tablets for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Northwind Pharmaceuticals LLC
See all →- ModerateDouble strength antibiotic bottles recalled over micro-organism on packaging coil
FDA (Drugs) · 2025-09-24
- ModerateFDA Recalls Glimepiride Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- HighPrescription drug recall for manufacturing quality control deviations
FDA (Drugs) · 2023-05-03
- ModerateAtorvastatin Calcium Tablets Recalled for Manufacturing Quality Violations
FDA (Drugs) · 2023-05-03
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
Same hazard · manufacturing deviation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
Similar recalls
- HighFDA recalls Buspirone Hydrochloride tablets for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAccord Healthcare Recalls Buspirone Hydrochloride Due to Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- HighFDA Recalls Accord Healthcare Buspirone 15 mg Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateBuspirone Hydrochloride tablets recalled for manufacturing practice deviations
FDA (Drugs) · 2023-03-08
- ModerateAccord Healthcare Recalls Buspirone Hydrochloride Tablets Due to Manufacturing Violations
FDA (Drugs) · 2023-03-08
- LowBuspirone Hydrochloride Tablets 5 mg Recalled for Subpotency
FDA (Drugs) · 2026-05-13